Expression of Podoplanin in Laryngeal Squamous Cell Carcinoma and Dysplasia

Abstract

Introduction: In human cancers, podoplanin expression and its correlation with tumour invasive potential raise its possible role as a diagnostic and prognostic marker for cancer. Aim:To investigate the immunohistochemical expression of podoplanin in laryngeal Squamous Cell Carcinoma (SCC) and dysplasia. Materials and Methods:This study included a total of 60 archived, formalin fixed, paraffin embedded tissue blocks of 40 cases of laryngeal SCC and 20 cases of dysplastic lesions. The samples were immunohistochemically analysed for podoplanin expression.Results: Podoplanin expression was significantly higher in laryngeal SCC (90%) than laryngeal dysplastic lesions (55%) (p-value=0.002). The expression of podoplanin was significantly increased with the higher grades of dysplasia (p-value=0.016). A significant positive correlation was detected between podoplanin expression in laryngeal SCC and depth of tumour invasion (p-value=0.035), and stage (p-value=0.026). Conclusion:The high expression of podoplanin in laryngeal SCC and its significant correlation with poor prognostic parameters recommends podoplanin as a prognostic marker in laryngeal SCC. In addition, increased podoplanin expression with higher grades of dysplasia, supports its role in malignant transformation and allows us to recommend its evaluation in premalignant lesions.

Immunohistochemical analysis of cancer-associated fibroblasts and podoplanin in head and neck cancer

“…In addition, PDPN showed a greater expression in oral SCC than in premalignant lesions, which in turn present a higher expression in cases with severe dysplasia (6,7), so PDPN is emerging as a possible biomarker of carcinogenesis and neoplastic development in early stages (6,26). In other forms of HNSCC this association is variable, whereas a similar relationship has been observed between tumour expression of PDPN with low survival and infiltrating phenotype in laryngeal and oesophageal SCC (27)(28)(29)(30). In other sites, such as the oropharynx, this…”